Kanakion Mm Pediátrico

Phytomenadione, the active ingredient in Kanakion Mm Pediátrico, is a vitamin K presented as a pediatric formulation for intramuscular, intravenous, and oral use. It is used to prevent and treat vitamin K deficiency bleeding and to reverse anticoagulant therapy in pediatric patients. GNH USA supplies Kanakion Mm Pediátrico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kanakion Mm Pediátrico (phytomenadione) acts on the vitamin K‑dependent coagulation pathway to correct clotting deficiencies.\n\n- Vitamin K deficiency bleeding (VKDB): prevents and treats hemorrhagic disease in newborns and infants.\n- Warfarin reversal: restores normal clotting factor activity in patients receiving vitamin K antagonists.\n- Pre‑operative prophylaxis: reduces bleeding risk in pediatric patients with low vitamin K status before surgery.

Kanakion Mm Pediátrico may cause adverse reactions, most of which are mild and transient.\n\nCommon Side Effects:\n- Injection site pain or erythema.\n- Mild bruising at the administration site.\n- Transient flushing or warmth.\n- Nausea or mild gastrointestinal upset.\n- Diarrhea.\n- Low‑grade fever.\n\nSerious or Rare Side Effects:\n- Anaphylactic or severe hypersensitivity reactions.\n- Acute hemolysis.\n- Severe bleeding despite therapy.\n- Thrombosis or clot formation.\n- Elevated liver enzymes.\n- Unexplained hypotension.

Use Kanakion Mm Pediátrico with attention to patient‑specific factors and monitoring.\n\n- Assess vitamin K status: evaluate baseline coagulation before administration.\n- Monitor coagulation parameters: check PT/INR after dosing.\n- Avoid in patients with known hypersensitivity to vitamin K or formulation excipients.\n- Use cautiously in newborns with cholestasis or hepatic impairment.\n- Do not co‑administer high‑dose vitamin E without monitoring for antagonistic effects.\n- Store at ambient temperature: keep in the original container, protect from moisture and light.

Phytomenadione can interact with several drugs, affecting coagulation or vitamin K metabolism.\n\nMajor Interactions (Avoid):\n- Warfarin: may reduce anticoagulant effect, leading to clotting risk.\n- Broad‑spectrum antibiotics (e.g., cefoperazone): can impair gut flora synthesis of vitamin K.\n- Bile acid sequestrants (e.g., cholestyramine): decrease oral vitamin K absorption.\n\nModerate Interactions (Monitor Closely):\n- Heparin: additive anticoagulant effect may increase bleeding risk.\n- Other vitamin K supplements: risk of excess vitamin K activity.\n- Oral contraceptives: may alter clotting factor levels, requiring monitoring.